In the article by Flamm et al.,1 the article type is amended.
The article, which discusses the potential benefits of the approval of terlipressin to treat hepatorenal syndrome in the United States, was first published as a Review. Due to the fact that it represents an opinion of the authors and some of them were advisers or consultants for the pharmaceutical company seeking FDA approval for terlipressin, the article type is changed to Perspective.
1. Flamm SL, Brown K, Wadei HM, Brown Jr RS, Kugelmas M, Samaniego‐Picota M, et al. The current management of hepatorenal syndrome–acute kidney injury in the United States and the potential of terlipressin. Liver Transpl 2021;27:1191‐1202.